Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer

Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Cancer Research (Impact Factor: 9.28). 03/2012; 72(5):1199-209. DOI: 10.1158/0008-5472.CAN-11-2759
Source: PubMed

ABSTRACT Metastasis to bone is a major cause of morbidity in breast cancer patients, emphasizing the importance of identifying molecular drivers of bone metastasis for new therapeutic targets. The endogenous cysteine cathepsin inhibitor stefin A is a suppressor of breast cancer metastasis to bone that is coexpressed with cathepsin B in bone metastases. In this study, we used the immunocompetent 4T1.2 model of breast cancer which exhibits spontaneous bone metastasis to evaluate the function and therapeutic targeting potential of cathepsin B in this setting of advanced disease. Cathepsin B abundancy in the model mimicked human disease, both at the level of primary tumors and matched spinal metastases. RNA interference-mediated knockdown of cathepsin B in tumor cells reduced collagen I degradation in vitro and bone metastasis in vivo. Similarly, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a reduction that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt. Notably, metastasis suppression by CA-074 was maintained in a late treatment setting, pointing to a role in metastatic outgrowth. Together, our findings established a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benefits of its selective inhibition in vivo.

Download full-text


Available from: Laura E Edgington-Mitchell, Mar 02, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor cells metastasize to distant organs through genetic and epigenetic alterations, including changes in microRNA (miR) expression. Here we find miR-22 triggers epithelial-mesenchymal transition (EMT), enhances invasiveness and promotes metastasis in mouse xenografts. In a conditional mammary gland-specific transgenic (TG) mouse model, we show that miR-22 enhances mammary gland side-branching, expands the stem cell compartment, and promotes tumor development. Critically, miR-22 promotes aggressive metastatic disease in MMTV-miR-22 TG mice, as well as compound MMTV-neu or -PyVT-miR-22 TG mice. We demonstrate that miR-22 exerts its metastatic potential by silencing antimetastatic miR-200 through direct targeting of the TET (Ten eleven translocation) family of methylcytosine dioxygenases, thereby inhibiting demethylation of the mir-200 promoter. Finally, we show that miR-22 overexpression correlates with poor clinical outcomes and silencing of the TET-miR-200 axis in patients. Taken together, our findings implicate miR-22 as a crucial epigenetic modifier and promoter of EMT and breast cancer stemness toward metastasis.
    Cell 07/2013; DOI:10.1016/j.cell.2013.06.026 · 33.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Skeletal metastases result in significant morbidity and mortality. This is particularly true of cancers with a strong predilection for bone, such as breast, prostate, and lung cancer. There is currently no reliable cure for skeletal metastasis, and limited palliative therapy options. The Wnt signaling pathway has been found to play an integral role in the process of skeletal metastasis, and could represent an important clinical target. Several experimental models of bone metastasis have been used to find new biomarkers and test new treatments. In this review, we will discuss what is known about the pathological process of bone metastasis, the roles of Wnt signaling in this process, and available experimental models and treatments.
    Chinese journal of cancer 01/2013; 32(7). DOI:10.5732/cjc.012.10218
  • Source